Form 4: Avalo Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Kevin Robert Lind, a Director of Avalo Therapeutics, Inc., received 1,352 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 1,352 Stock Option (Right to Buy) at $12.29 ($16,616) on September 30, 2026; holds 1,352 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kevin Robert Lind — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Stock Option (Right to Buy) | 1,352 | $12 | $16.6K | 1,352 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (1,352 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., neutral, Kevin Robert Lind
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.